✦ LIBER ✦

Paclitaxel and bevacizumab as first-line treatment in elderly women with HER-2 negative locally advanced or metastatic breast cancer: Preliminary results a multicenter phase II trial from Hellenic Oncology Research Group

✍ Scribed by Vamvakas, L.; Karampeazis⁎, A.; Nikolaou, Ch.; Ardavanis, A.; Saloustros, E.; Kalbakis, K.; Zafeiriou, Z.; Stoltidis, D.; Kalykaki, A.; Georgoulias, V.; Mavroudis, D.

Book ID: 121914821
Publisher: Elsevier
Year: 2012
Tongue: English
Weight: 71 KB
Volume: 3
Category: Article
ISSN: 1879-4068
DOI: 10.1016/j.jgo.2012.10.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cyclophosphamide and liposomal-encapsula

Cyclophosphamide and liposomal-encapsulated doxorubicin (MYOCET®) in elderly women with HER-2 negative locally advanced or metastatic breast cancer: Preliminary results of a multicenter phase II trial from the Hellenic Oncology Research Group

✍ Karampeazis⁎, A.; Ardavanis, A.; Kentepozidis, N.; Nikolaou, Ch.; Bozionelou, V. 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 80 KB

Safety results from a phase III study (T

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

✍ I. Lang; M.J. Inbar; Z. Kahán; R. Greil; S. Beslija; S.M. Stemmer; B. Kaufman; Z 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 302 KB

P.39 Docetaxel plus epirubicin (DE) vs d

P.39 Docetaxel plus epirubicin (DE) vs docetaxel plus capecitabine (DC) as 1st line treatment in patients with locally advanced and metastatic breast cancer: a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)

✍ Vamvakas, L.; Karampeazis, A.; Ardavanis, A.; Souglakos, I.; Kalbakis, K.; Varda 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB